BridgeMD
New treatment option for Cerebrovascular Accident
Official title Neurorehabilitation Through Hippotherapy of a Brain Stroke
ClinicalTrials.gov ID: NCT04759326
What this study is testing
- What it's testing
- Cerebrovascular accident [CVA] (medical term for stroke) is a high burden worldwide disorder and the second leading cause of disability. As illustrated by the number of survivors that remain disabled after a CVA (2 out of 3 according to the US National Stroke Association), recovery is limited, and novel neurorehabilitation approaches are urgently needed.
- Time commitment: about 22 weeks
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Age ≥ 18 years old
- Ischemic or haemorrhagic stroke according to ICD 10 I61-I69 (30)
- Inclusion \> 3 months post-stroke
- Deficit still existing (Rankin score ≥ 3 and ≤ 4 at inclusion)
- Existing declaration of informed consent
You likely can't join if
- Major cognitive impairment affecting comprehension (Mini Mental State Examination test \< 24 points)
- Global or sensory aphasia
- Neurological or psychiatric co-morbidity (other than mild-to-moderate post-stroke depression)
- Evidence of an uncontrolled seizure disorder
- Substance abuse
- History of uncontrolled pain
See the full eligibility criteria
- Age ≥ 18 years old
- Ischemic or haemorrhagic stroke according to ICD 10 I61-I69 (30)
- Inclusion \> 3 months post-stroke
- Deficit still existing (Rankin score ≥ 3 and ≤ 4 at inclusion)
- Existing declaration of informed consent
- Affiliation of the patient to a social security scheme
- Minimal abduction of the hip of 25 degrees bilateral with no history of hip dislocation and/or dysplasia
- Certificate of non-contraindication issued by the referring physician
- Major cognitive impairment affecting comprehension (Mini Mental State Examination test \< 24 points)
- Global or sensory aphasia
- Neurological or psychiatric co-morbidity (other than mild-to-moderate post-stroke depression)
- Evidence of an uncontrolled seizure disorder
- Substance abuse
- History of uncontrolled pain
- History of allergic reactions to dust and/or horsehair, or severe asthma
- Overweight (≥ 110 kg)
- Contraindications to physical activity
- Inability or medical contraindication to travel to the Equiphoria Institute by personal car or taxi
- History of horse riding or hippotherapy care during the last 6 months
- Pregnant or lactating women
- Patients participating in other biomedical research or in a period of exclusion
The study team makes the final eligibility decision.
Where it's taking place
- La Canourgue, France
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The study runs about 22 weeks per participant, based on its public description. The team confirms the exact schedule and number of visits before you enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include La Canourgue, France. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.